Pfenex Inc. (PFNX): Patricia Lady , Chief Accounting Officer of Pfenex Inc. sold 2,000 shares on May 24, 2016. The Insider selling transaction was reported by the company on May 25, 2016 to the Securities and Exchange Commission. The shares were sold at $6.52 per share for a total value of $13,043.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Dec 17, 2015, Chemical Co /de/ Dow (10% owner) sold 600,000 shares at $11.75 per share price.On Dec 3, 2015, Patrick K. Lucy (Chief Business Officer) sold 1,500 shares at $14.15 per share price.Also, On Dec 2, 2015, Henry W. Jr. Talbot (VP of Operations) sold 2,000 shares at $15.08 per share price.On Dec 2, 2015, Bertrand C. Liang (Chief Executive Officer) sold 5,000 shares at $15.21 per share price.
Pfenex Inc: On Friday, May 20, 2016 heightened volatility was witnessed in Pfenex Inc which led to swings in the share price. The shares opened for trading at $6.03 and hit $6.53 on the upside , eventually ending the session at $6.25, with a gain of 3.48% or 0.21 points. The heightened volatility saw the trading volume jump to 57,780 shares. The 52-week high of the share price is $24.41 and the company has a market cap of $146,100 M . The 52-week low of the share price is at $5.88.
Company has been under the radar of several Street Analysts.Pfenex Inc is Reiterated by Barclays to Overweight while Lowering the Price Target of the company shares to $ 14 from a previous price target of $28 . The Rating was issued on May 24, 2016.
Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The Company’s lead product candidate is PF582 a biosimilar candidate to Lucentis (ranibizumab). The Company is conducting a Phase Ib/IIa trial for PF582 in patients with wet age-related macular degeneration (wet AMD). The Company’s next most advanced product candidate is PF530 a biosimilar candidate to Betaseron (interferon beta-1b). The Company’s pipeline includes five other preclinical biosimilar products under development such as PF726 PF529 PF688 PF694 and PF444. It is also developing a vaccine Px563L which is an anthrax vaccine candidate; a generic product PF708 and next generation biologic candidates. The Company’s product candidates are enabled by its patented protein production platform Pfenex Expression Technology.